Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,601–1,689 of 1,689
Urfer-Buchwalder, A., & Urfer, R. (2017) · Scientific Reports · doi:10.1038/srep40668 · Cited by 20
Papadopoulos, N., Suelves, N., Perrin, F., Vadukul, D. M., Vrancx, C., Constantinescu, S. N., & Kienlen-Campard, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112753 · Cited by 20
“homeostasis in the brain, is the principal risk factor for sporadic AD [123,155].”
BackgroundGenetic architecture of plasma Alzheimer disease biomarkers
Bradley, J., Gorijala, P., Schindler, S. E., Sung, Y. J., Ances, B., the Alzheimer’s Disease Neuroimaging Initiative, T. H. C. P., Ertekin-Taner, N., Younkin, S., Golde, T., Price, N., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad087 · Cited by 20
Apolipoprotein E ε4 modulates astrocyte neuronal support functions in the presence of amyloid‐β
Fleeman, R. M., Kuhn, M. K., Chan, D. C., & Proctor, E. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15781 · Cited by 20
“…from APOE4 astrocytes in the presence of A β leads to lack of neuronal support and consequent increased risk of neuron synaptic loss, contributing to a disease-promoting environment and increased risk for AD in APOE4 carriers (Corder et al., 1993; Farrer et al., 1997; Strittmatter & Roses, 1996).”
BackgroundCurrent insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
Differential metabolism of ApoE isoforms in plasma and CSF
Wahrle, S. E., & Holtzman, D. M. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00185-7 · Cited by 19
Ramsden, C. E., Keyes, G. S., Calzada, E., Horowitz, M. S., Zamora, D., Jahanipour, J., Sedlock, A., Indig, F. E., Moaddel, R., Kapogiannis, D., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220071 · Cited by 19
“ApoE is enriched in the central core of neuritic plaques [23, 24], and APOE variants are the strongest genetic risk factor for sAD [25–28].”
Wu, J., Hasselgren, C., Zettergren, A., Zetterberg, H., Blennow, K., Skoog, I., & Halleröd, B. (2020) · Aging & Mental Health · doi:10.1080/13607863.2018.1531368 · Cited by 18
Walsh, T., Duff, L., Riviere, M. E., Tariot, P. N., Doak, K., Smith, M., Borowsky, B., Lopez Lopez, C., Arratia, P. C., Liu, F., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.27 · Cited by 18
“Here we describe the tactics and strategies and their success in the outreach, recruitment, screening, and enrollment of participants into the API Generation Program, with a specific focus on identifying and enrolling cognitively unimpaired APOE ε4 HMs given the 2-3% prevalence of this genotype in the population (16,…”
MethodVenzi, M., Tóth, M., Häggkvist, J., Bogstedt, A., Rachalski, A., Mattsson, A., Frumento, P., & Farde, L. (2017) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170006 · Cited by 18
“In clinical neuroscience research a strong interest for ApoE has arisen from the finding that the 4 allele is an established risk factor for Alzheimer’s disease (AD) [7] while the 2 allele, at least in some human samples, appears to be protective against AD in comparison to 3 [8, 9].”
BackgroundHu, Y., Meuret, C., Martinez, A., Yassine, H. N., & Nedelkov, D. (2021) · Journal of Lipid Research · doi:10.1194/jlr.ra120000919 · Cited by 18
Gal, J., Katsumata, Y., Zhu, H., Srinivasan, S., Chen, J., Johnson, L. A., Wang, W.-X., Golden, L. R., Wilcock, D. M., Jicha, G. A., et al. (2022) · The American Journal of Pathology · doi:10.1016/j.ajpath.2021.11.013 · Cited by 17
Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis
Mercer, J. L., Argus, J. P., Crabtree, D. M., Keenan, M. M., Wilks, M. Q., Chi, J.-T. A., Bensinger, S. J., Lavau, C. P., & Wechsler, D. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129776 · Cited by 17
“The expression of APOE, a key lipoprotein and carrier of cholesterol in the brain, has been shown to be a highly significant risk factor in the development of late-onset AD [23, 80].”
BackgroundPolygenic score modifies risk for Alzheimer's disease in APOE ε4 homozygotes at phenotypic extremes
Huq, A. J., Fulton‐Howard, B., Riaz, M., Laws, S., Sebra, R., Ryan, J., Alzheimer's Disease Genetics Consortium, Renton, A. E., Goate, A. M., Masters, C. L., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12226 · Cited by 17
Tate, M., Wijeratne, H. R. S., Kim, B., Philtjens, S., You, Y., Lee, D., Gutierrez, D. A., Sharify, D., Wells, M., Perez‐Cardelo, M., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14243 · Cited by 21
CRP gene variation affects early development of Alzheimer's disease-related plaques
Kok, E., Alanne-Kinnunen, M., Isotalo, K., Luoto, T., Haikonen, S., Goebeler, S., Perola, M., Hurme, M. A., Haapasalo, H., & Karhunen, P. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-96 · Cited by 16
“Various studies have found ORs of between 2 and 8, as well as lowering the age of onset, with ε4 allele dosage [5,6].”
BackgroundApolipoprotein E1 Baden (Arg180→Cys)
Hoffmann, M. M., Scharnagl, H., Köster, W., Winkler, K., Wieland, H., & März, W. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00372-7 · Cited by 16
Therapeutic Idol reduction ameliorates amyloidosis and improves cognitive function in APP/PS1 mice
Gao, J., Littman, R., Diamante, G., Xiao, X., Ahn, I. S., Yang, X., Cole, T. A., & Tontonoz, P. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00518-19 · Cited by 15
“Down: Flt1, Lamc1, Vtn Cajal-Retzius neuron 46 (1) Wnt signaling pathway Down: Csnk1a1, Tbl1x, Ccnd2, Btrc Neuron dentate 90 (2) Alzheimer’s disease Up: Itpr1.”
Pankiewicz, J. E., Lizińczyk, A. M., Franco, L. A., Diaz, J. R., Martá-Ariza, M., & Sadowski, M. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01261-z · Cited by 15
“Possession of a single and double ε4 allele increases AD risk ~ 3 and ~ 15-fold relative to ε3/ ε3 homozygotes, which is the most common APOE genotype, respectively [20, 55, 81].”
BackgroundPrasinou, P., Dafnis, I., Giacometti, G., Ferreri, C., Chroni, A., & Chatgilialoglu, C. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.07.001 · Cited by 15
Yamanouchi, Y., Arinami, T., Tsuchiya, S., Miyazaki, R., Takaki, H., Takano, T., & Hamaguchi, H. (1994) · Japanese journal of human genetics · doi:10.1007/bf01874050 · Cited by 15
Newhouse, Y., Peters-Libeu, C., & Weisgraber, K. H. (2005) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309105032410 · Cited by 15
“ApoE also plays a key role in neurobiology and apoE4 is a major risk factor for Azheimer’s disease (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993) and other forms of central nervous system stress (Mayeux et al., 1995; Roses & Saunders, 1997; Slooter et al., 1997; Teasdale et…”
BackgroundJones, S. E., Hees, V. T. V., Mazzotti, D. R., Marques-Vidal, P., Sabia, S., der Spek, A. V., Dashti, H. S., Engmann, J., Kocevska, D., Tyrrell, J., et al. (2018) · doi:10.1101/303925 · Cited by 14
Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 16
“In support of this is mainly the evidence of the very high frequency in late-onset AD subjects of the ε 4 allele of apolipoprotein E (ApoE4), an apolipoprotein primarily involved in the lipid transport within the body [20].”
Xu, G., Karch, C., Li, N., Lin, N., Fromholt, D., Gonzales, V., & Borchelt, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003159 · Cited by 14
“the apolipoprotein E (Apo E) gene [2].”
Supasitthumrong, T., Tunvirachaisakul, C., Aniwattanapong, D., Tangwongchai, S., Chuchuen, P., Tawankanjanachot, I., Snabboon, T., Hemrungrojn, S., Carvalho, A. F., & Maes, M. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190114 · Cited by 13
“Indeed, one E4 copy (especially E3/E4) increases risk for AD, while two E4copies(E4/E4)increaseriskconsiderably[40,41].”
Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
Komai, M., Noda, Y., Ikeda, A., Kaneshiro, N., Kamikubo, Y., Sakurai, T., Uehara, T., & Takasugi, N. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100510 · Cited by 13
“In particular, ApoE4 is known to be the strongest genetic risk factor for sporadic AD, and the number of ε 4 genes affects the risk and accelerates the onset of AD (72).”
BackgroundBar, R., Boehm‐Cagan, A., Luz, I., Kleper‐Wall, Y., & Michaelson, D. M. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.08.003 · Cited by 13
Isoform- and cell-state-specific APOE homeostasis and function
Lindner, K., & Gavin, A.-C. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01470 · Cited by 13
“…polymorphism in components of the APOE pathway – for example APOE itself, its receptor, the trigger receptor expressed on myeloid cells 2 (TREM2; Corder et al., 1993; Guerreiro et al., 2013) or the adenosine triphosphate (ATP) binding cassette subfamily A member 1 (ABCA1) cholesterol…”
BackgroundApolipoprotein E4 exhibits intermediates with domain interaction
Dolai, S., Cherakara, S., & Garai, K. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140535 · Cited by 13
Fan, Q.-W., Iosbe, I., Asou, H., Yanagisawa, K., & Michikawa, M. (2001) · AGE · doi:10.1007/s11357-001-0001-9 · Cited by 13
Biundo, F., Ishiwari, K., Del Prete, D., & D’Adamio, L. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.10.009 · Cited by 13
“…risk factor for lateonset familial and sporadic AD, and its gene dose is correlated with increased risk and earlier age at onset of the disease (Corder et al., 1993; Saunders et al., 1993), although the risk of developing AD attributable to ApoE4 varies by geographical region (Bosco et al.,…”
Membership in genetic groups predicts Alzheimer disease.
Corder, E. H., Huang, R., Cathcart, H. M., Lanham, I. S., Parker, G. R., Cheng, D., Smith, S., & Poduslo, S. E. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.89 · Cited by 13
Self-citationKAPLITT, M., GOURAS, G. K., MAKIMURA, H., JOVANOVIC, J., SWEENEY, D., GREENGARD, P., RELKIN, N. R., & GANDY, S. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32597.x · Cited by 12
Unveiling recent and ongoing adaptive selection in human populations
Gao, Z. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002469 · Cited by 12
“…one overlaps with the APOE ε 4 allele that is associated with reduced lifespan and increased risk of Alzheimer’s disease and cardiovascular diseases [55,56]; the other locus contains variants that are close to a nicotine receptor gene CHRNA3 and associated with increased smoking quantity [57].”
BackgroundACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Alavez-Rubio, J. S., & Juarez-Cedillo, T. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190823125245 · Cited by 12
Rare APOE Missense Variants—Can We Overcome APOE ε4 and Alzheimer Disease Risk?
Rabinovici, G. D., & Dubal, D. B. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0854 · Cited by 12
Apolipoprotein E Highly Correlates with AβPP- and Tau-Related Markers in Human Cerebrospinal Fluid
Vuletic, S., Li, G., Peskind, E. R., Kennedy, H., Marcovina, S. M., Leverenz, J. B., Petrie, E. C., Lee, V. M.-Y., Galasko, D., Schellenberg, G. D., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15307 · Cited by 12
“Apolipoprotein E (apoE) genotype is currently the only known and well-established genetic risk factor for development of AD, with APOE ε 4 isoform conferring an increased risk and accelerated development of AD, and APOE ε 2 isoform apparently being protective against AD [5,8,23,27].”
Giannisis, A., Al-Grety, A., Carlsson, H., Howell, J. C., Hu, W. T., Kultima, K., & Nielsen, H. M. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01262-1 · Cited by 11
“Harboring the ε4 allele is linked to a higher risk of AD and a younger age of disease onset [8].”
BackgroundHossain, M. M., Adhikari, J., Dutta, A., Khandaker, A., Islam, S., Rahman, M. M., & Shibly, A. Z. (2025) · PLOS One · doi:10.1371/journal.pone.0331339 · Cited by 11
Wei, P., Lin, K., Chen, X., Fang, C., Qiu, L., Hu, J., & Chang, J. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70306 · Cited by 11
“The risk of AD increases in a gene dose-dependent manner from APOE2 to APOE4, and APOE4 is associated with a lower age at onset of AD [19, 20].”
Tavori, H., Fan, D., Giunzioni, I., Zhu, L., Linton, M. F., Fogo, A. B., & Fazio, S. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049874 · Cited by 10
Eid, F., Boushehri, M., Boucher, C., Rajkanth, N., Sa, A. F., Alhoutan, T., Vavetsi, K., Dibart, S., & Ma, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202403117rr · Cited by 10
A framework for modeling epistatic interaction
Blumenthal, D. B., Baumbach, J., Hoffmann, M., Kacprowski, T., & List, M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa990 · Cited by 10
Takacs, C. N., Andreo, U., Belote, R. L., Pulupa, J., Scull, M. A., Gleason, C. E., Rice, C. M., & Simon, S. M. (2017) · Traffic · doi:10.1111/tra.12467 · Cited by 10
Do Alzheimer's Disease Risk Gene Products Actually Act in Microglia?
Hashioka, S., Inoue, K., Takeshita, H., & Inagaki, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.589196 · Cited by 9
“The strongest genetic risk factor for late-onset Alzheimer’s disease (AD) is allele ε4 of the apolipoprotein E (ApoE) gene, which was discovered in 1993 (Corder et al., 1993).”
BackgroundMurakami, R., Watanabe, H., Hashimoto, H., Kashiwagi-Hakozaki, M., Hashimoto, T., Karch, C. M., the Dominantly Inherited Alzheimer Network (DIAN), Iwatsubo, T., & Okano, H. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.1709-23.2024 · Cited by 9
Exploring the Genetic Heterogeneity of Alzheimer’s Disease: Evidence for Genetic Subtypes
Elman, J. A., Schork, N. J., Rangan, A. V., & Initiative, F. T. A. D. N. (2024) · Journal of Alzheimer’s Disease · doi:10.3233/jad-231252 · Cited by 9
LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice
Stukas, S., Freeman, L., Lee, M., Wilkinson, A., Ossoli, A., Vaisman, B., Demosky, S., Chan, J., Hirsch-Reinshagen, V., Remaley, A. T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049940 · Cited by 9
Strickland, M. R., Wang, Z., Golden, L. R., Wang, H., Lu, P., Ren, Y., Tabor, G. T., Zhao, N., Ulrich, J. D., Han, X., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101000 · Cited by 8
Rodríguez, A., Calero, O., Veiga, S., Menacho-Román, M., Arribas, I., Cano, L., García-Ribas, G., & Calero, M. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01811-w · Cited by 8
“It is well established that the APOE gene, particularly the ε4 allele, is the most potent genetic risk factor for late-onset AD [6, 7, 9, 36] and is also associated with an increased risk and severity of adverse effects, specifically ARIA, in patients undergoing anti-amyloid therapies, such as…”
Bonnar, O., Shaw, K., Anderle, S., Grijseels, D. M., Clarke, D., Bell, L., King, S. L., & Hall, C. N. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231172842 · Cited by 8
“11,12 ApoE is involved in lipid transportation and is produced mainly by astrocytes, but also by vascular mural cells and microglia, and neurons under stress conditions.”
BackgroundIttisoponpisan, S., & David, A. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00077 · Cited by 8
Goltermann, J., Repple, J., Redlich, R., Dohm, K., Flint, C., Grotegerd, D., Waltemate, L., Lemke, H., Fingas, S. M., Meinert, S., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.006 · Cited by 8
Yuri, T., Degrieck, R., Minczakiewicz, D., Sato, H., Kamada, J., Nakazawa, T., Vandenbroucke, I., Aoyagi, K., & Nojima, H. (2023) · Exploration of Neuroscience · doi:10.37349/en.2023.00024 · Cited by 8
Apolipoprotein E Expression and Purification
Newhouse, Y., & Weisgraber, K. H. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-744-0_10 · Cited by 8
Focused ultrasound‐mediated APOE4 knockdown in mouse brain
Zheng, K., Tsitsos, F. N., Batts, A. J., Ji, R., Nuriel, T., Konofagou, E. E., & Leong, K. W. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70464 · Cited by 8
Miyoshi, E., Morabito, S., & Swarup, V. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105530 · Cited by 7
Yamauchi, K., Iwasaki, S., & Kawakami, Y. (2019) · Bioscience Reports · doi:10.1042/bsr20190184 · Cited by 7
Baron, M., Jimenez‐Escrig, A., Orensanz, L., Simon, J., & Perez‐Tur, J. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20028 · Cited by 7
“It seems to act in a dosedependent manner, and is related with an earlier age at-onset [Corder et al., 1993].”
BackgroundDeterminants, mechanisms, and functional outcomes of myeloid cell diversity in cancer
Caronni, N., Montaldo, E., Mezzanzanica, L., Cilenti, F., Genua, M., & Ostuni, R. (2021) · Immunological Reviews · doi:10.1111/imr.12944 · Cited by 6
APOE genotype-dependent differences in human astrocytic energy metabolism
Budny, V., Bodenmann, C., Zürcher, K. J., Krüger, M., de Leeuw, S. M., Weber, R. Z., Rust, R., Ravotto, L., Ruminot, I., Barros, L. F., et al. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1603657 · Cited by 6
“APOE4 increases the risk for developing AD by 2.5-4-fold in heterozygous and 12-15-fold in homozygous carriers (Corder et al., 1993; Grupe et al., 2007; Corneveaux et al., 2010), however the risk is affected by factors such as sex or population ancestry (Belloy et al., 2023).”
InfluentialApolipoprotein E polymorphism and dendritic shape in hippocampal interneurons
Schönheit, B., Glöckner, F., & Ohm, T. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.016 · Cited by 6
Garrahy, J. P. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251350338 · Cited by 6
Rapid Dissection of the Genetic Risk of Age-Related Macular Degeneration
Haines, J. L., & Pericak-Vance, M. A. (2007) · JAMA · doi:10.1001/jama.297.4.401 · Cited by 5
Self-citationMicroglia-derived APOE2 improves remyelination even in the presence of endogenous APOE4
Nolt, G. L., Golden, L. R., Thorpe, S. P., Funnell, J. L., Stephens, I. O., Hernandez, G., MacLean, S. M., Lucido, C. C., Brock, C. R., Pallerla, A. V., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03639-5 · Cited by 5
“Compared to the most commonly expressed E3 allele, carriage of the E4 allele increases risk and progression of both AD and MS [16–22].”
Stratikos, E., & Chroni, A. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0886-5 · Cited by 5
Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue
Williams, B., Convertino, M., Das, J., & Dokholyan, N. V. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.08.026 · Cited by 5
Protective ApoE variants support neuronal function by extracting peroxidated lipids
Ralhan, I., Do, A. D., Bae, J.-Y., Feringa, F. M., Cai, W., Chang, J., Chik, K., Lee, N. Y., Gerry, C., van der Kant, R., et al. (2025) · bioRxiv · doi:10.1101/2025.03.05.641722 · Cited by 4
Conformational analysis of apolipoprotein E3/E4 heteromerization
Tu, K., Abhari, D., & Narayanaswami, V. (2019) · The FEBS Journal · doi:10.1111/febs.14794 · Cited by 4
Bagaria, J., Moon, Y., Bagyinszky, E., Shim, K. H., An, S. S. A., Kim, S., & Han, S. H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.899644 · Cited by 4
Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
ApoE expression across the CNS: Who, What, Where, When, and How (much)?
Nolt, G. L., Lucido, C. C., Smith, L. M., & Johnson, L. A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00028-x · Cited by 2
Andrieieva, D., Falltrick, I., Chiang, C.-Y., Beaumont, B., Guen, Y. L., Liu, C., Pergolesi, S., Ma, C.-T., Jackson, M. R., Hyman, B. T., et al. (2026) · doi:10.64898/2026.05.09.26352797 · Cited by 2
Hernandez Arriaza, R., Reil, D., Fatuzzo, N., Fu, M., Dai, Y., Fernandez Martinez, D., Jiang, H., Holtzman, D. M., Greicius, M. D., & Khosla, C. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00503 · Cited by 2
Roberts, B. R., Laffoon, S. B., Roberts, A. M., Porter, T., Fowler, C., Masters, C. L., Dratz, E. A., Laws, S. M., & for the AIBL research group (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220075 · Cited by 2
“APOE ε 4 is the most jeopardizing allele, conferring a dose-dependent increase to the risk for AD and reducing the mean age of onset about ten years in homozygous ε 4 persons, compared to persons without ε 4 allele [6, 7].”
Locus- and Gene-Level Insights into the Inverse Association Between Alzheimer’s Disease and Cancer
Debnath, D., Housini, M., Sariya, S., Phillips, N. R., Pathak, G. A., & Barber, R. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062900 · Cited by 2
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Tian, Y., Hornburg, K., Austin, W., Cook, J. J., Qi, Y., White, L. E., Killmar, J. T., Kaczorowski, C. C., Ashbrook, D. G., Johnson, G. A., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-025-02199-4 · Cited by 1
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Frisch, C., Baker, L., Srinivasan, G., Mintah, A. E., Leyasi, S., Pedroza, M., Galyon, B., & Brafman, D. A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1856154
Jackson, R. J., Dierksmeier, S., Nishtar, M., Meltzer, J., Balduin, F., Beaumont, B., Fan, Z., Sergienko, E., Olson, S., Jackson, M. R., et al. (2026) · doi:10.64898/2026.06.09.730809
Nolt, G. L., MacLean, S. M., Golden, L. R., Thorpe, S. P., Stephens, I. O., Funnell, J. L., Brock, C. R., Lucido, C. C., Smith, L., Hernandez, G., et al. (2027) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.08.005
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
Mejia-Garcia, A., Valderrama-Carmona, P., Zheng, T. M., Wang, Z., Tsao, H. M., Jung, J., Orozco, C. A., Su, C.-Y., & Zhou, S. (2026) · doi:10.64898/2026.09.26.26364080
Koivumäki, M., Martiskainen, H., Takalo, M., Lehtisalo, J., Ngandu, T., Snellman, A., Hiltunen, M., & Rinne, J. O. (2025) · doi:10.21203/rs.3.rs-7823342/v1
A unifying hypothesis of alzheimer’s disease: III—Risk factors
Heininger, K. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(200001)15:1<1::aid-hup153>3.0.co;2-1
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.